News Image

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Provided By GlobeNewswire

Last update: Feb 26, 2025

– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 –

– Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures –

Read more at globenewswire.com

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (6/2/2025, 4:04:09 PM)

15.4

+1.25 (+8.83%)



Find more stocks in the Stock Screener

Follow ChartMill for more